Revealed: pharmaceutical companies leading the way in artificial intelligence
We analysed thousands of records from GlobalData's proprietary themes, jobs, deals and patents databases to identify the most active pharma…
By
Biopharmaceutical Industry
Latest in
Biopharmaceutical Industry
Filings buzz in pharma: 15% decrease in internet of things mentions in Q2 2022
We analyse companies' annual reports and other filings to spot topics receiving most attention.
By
Complete responses reported for Nkarta’s off-the-shelf NK cell therapies
On April 25, Nkarta, a biopharmaceutical company developing off-the-shelf engineered natural killer (NK) cell therapies, announced highly promising results from…
By
CTI BioPharma’s pacritinib fails to meet primary goal in Covid study
Pacritinib was found to be well-tolerated in the PRE-VENT trial with reduced number of grade 3+ events.
AzurRx BioPharma begins trial of niclosamide tablets for Covid-19
AzurRx BioPharma has started its Phase II clinical trial to evaluate micronised oral niclosamide tablets, known as FW-1022, in patients…
Kala’s dry eye syndrome steroid likely to be FDA approved; mixed potential on uptake
by William Newton in Texas. Kala Biopharmaceuticals’ ocular steroid Eysuvis (loteprednol etabonate) has a high probability of attaining the US…
By
ARCA biopharma’s AB201 secures IND approval for Covid-19 trial
The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application of ARCA biopharma’s potential drug candidate AB201 (rNAPc2) to…
Clover’s adjuvant choice for Covid-19 an edge, but comparison with IMV’s, Novavax’s vaccines limited
by Reynald Castaneda in London. Clover Biopharmaceuticals' Covid-19 protein subunit vaccine could potentially have the upper hand versus Novavax’s and IMV’s due to…
By